Overview
Description
The Accelerating Medicines Partnership- Alzheimer’s Disease Target Discovery and Preclinical Validation (AMP-AD) has supported the generation of whole genome data from three studies: the MAYO RNAseq Study, the Mount Sinai Brain Bank, and the ROSMAP study. The Genome Center for AD (GCAD) has partnered with the investigators of these studies to generate a joint genotype called dataset consisting of the AMP-AD genomes along with the ADSP and other Alzheimer’s Disease and Related Dementia projects. Data were obtained directly from each AMP-AD investigator and harmonized by the Genome Center for AD on the VCPA1.1 pipeline. Additional information about each of the three studies can be obtained from the AMP-AD Knowledge Portal.
Principal Investigators
- Bin Zhang, PhD — Icahn School of Medicine Mount Sinai School of Medicine
- David Bennett, MD — Rush University Medical Center
- Nilufer Ertekin-Taner, MD, PhD — Mayo Clinic
Funding Sources
ROSMAP: U01 AG046152, R01 AG043617, R01 AG042210, R01 AG036042, R01 AG036836, R01 AG032990, R01 AG18023, RC2 AG036547, P50 AG016574, U01 ES017155, KL2 RR024151, K25 AG041906-01, R01 AG30146, P30 AG10161, R01 AG17917, R01 AG15819, K08 AG034290, P30 AG10161 and R01 AG11101. Mayo: U01AG046139, U01AG046161. Mount Sinai Brain Bank: R01AG046170, RF1AG054014, RF1AG057440, R01AG057907, NIH HHSN271201300031C
Publications
- Allen M. Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. Scientific data. 2016 Oct 11. PubMed link
- De Jager PL. A multi-omic atlas of the human frontal cortex for aging and Alzheimer's disease research. Scientific data. 2018 Aug 7. PubMed link
- Wang M. The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. Scientific data. 2018 Sep 11. PubMed link